China SXT Pharmaceutics announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026. The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 3, 2026. Upon the market opening on February 3, 2026, the Company’s Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTC:
- China SXT announces initiative to apply AI tech across TCM supply chain
- China SXT Pharmaceuticals Raises $9.1 Million in Registered Direct Offering with Pre-Funded Warrants
- China SXT Pharmaceuticals announces $10M registered direct offering
- Why Is Penny Stock China SXT (SXTC) Up Almost 200% Today?
- Midday Fly By: Defense stocks surge on Trump budget request